Dr Phillips on the Evaluation of Frontline Treatment With Acalabrutinib Plus BR in MCL

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.

Related Keywords

Tycel Phillips ,Department Of Hematology Hematopoietic Cell Transplantation ,Division Of Lymphoma ,Hematopoietic Cell Transplantation ,City Of Hope ,Onclive Tv ,Mantle Cell Lymphoma ,Calquence ,Acalabrutinib ,Bendamustine ,Rituximab ,Rituxan ,Nct02717624 ,Echo ,